The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against TG Therapeutics, Inc. (“TG Therapeutics” or “the Company”) (NASDAQ: TGTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between January 15, 2020 and May 31, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before September 16, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. TG Therapeutics’ clinical trials for Ublituximab and Umbralisib revealed concerns about the benefit-risk ratio and overall survival data for the drugs. Based on these issues, it was unlikely that the Company would achieve FDA approval for the Umbralisib MZL/FL NDA, the U2 BLA, the U2 sNDA, or the Ublituximab RMS BLA in their current form. The Company overstated the commercial prospects of Ublituximab and Umbralisib. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about TG Therapeutics, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005874/en/